Showing 7051-7060 of 21434 results for "".
- Understanding Headaches in Children: A Multifaceted Approach for Effective Managementhttps://reachmd.com/news/understanding-headaches-in-children-a-multifaceted-approach-for-effective-management/2471201/Headaches in children are a multifaceted issue, often intertwined with psychological and physical factors. Understanding these complexities is crucial for healthcare professionals to provide effective management and treatment. Identifying Red a
- Understanding Hyperacute Outer Retinal Dysfunction in Childrenhttps://reachmd.com/news/understanding-hyperacute-outer-retinal-dysfunction-in-children/2471196/A recent study highlights a new retinal disorder, hyperacute outer retinal dysfunction (HORD), affecting children post-febrile illness, characterized by severe vision loss and subsequent recovery. Exploring a New Pediatric Retinal Disorder Afte
- Unveiling New Genetic Pathways in Kidney Disease: A Step Toward Personalized Medicinehttps://reachmd.com/news/unveiling-new-genetic-pathways-in-kidney-disease-a-step-toward-personalized-medicine/2471249/Recent advancements in genetic research have illuminated new pathways for understanding and treating kidney disease, potentially transforming patient care and outcomes. Revolutionary Genetic Discoveries Pave New Pat
- Genetic Diversity: A New Lens on Retinal Aging and Neurodegenerationhttps://reachmd.com/news/genetic-diversity-a-new-lens-on-retinal-aging-and-neurodegeneration/2471197/Exploring How Genetics Shape Retinal Aging and Brain Health Recent studies reveal that genetic diversity significantly influences the aging process of the retina and offers insights into broader neurodegenerative conditions. These findings could
- The Expansion and Challenges of Supervised Toothbrushing Programs in Englandhttps://reachmd.com/news/the-expansion-and-challenges-of-supervised-toothbrushing-programs-in-england/2471187/Supervised toothbrushing programs are gaining traction in England as a strategic initiative to combat childhood tooth decay. Despite progress, significant challenges remain that must be addressed to ensure all children benefit from these preventive measures.
- Decoding Schizophrenia: Genetic Mutation's Role in Psychosis Unveiledhttps://reachmd.com/news/decoding-schizophrenia-genetic-mutations-role-in-psychosis-unveiled/2471190/A groundbreaking study has identified a genetic mutation that increases enzyme levels linked to schizophrenia behaviors in mice, establishing a novel genetic connection to psychosis. This research offers new insights into the complex genetics of schizo
- How Parental Alcohol Use Raises Offspring's Cancer Riskshttps://reachmd.com/news/how-parental-alcohol-use-raises-offsprings-cancer-risks/2471193/Emerging research reveals that parental alcohol consumption can significantly increase the risk of liver cancer in offspring through heritable mitochondrial disruptions. Understanding Hereditary Impacts of Alcohol Use The intergeneratio
- Hydrodissection: A Promising Adjunct for Postamputation Pain Managementhttps://reachmd.com/news/hydrodissection-a-promising-adjunct-for-postamputation-pain-management/2471200/A novel approach combining hydrodissection with opioid therapy may offer improved outcomes for patients suffering from postamputation pain, especially in conflict-affected areas. Understanding Hydrodissection Hydrodissection is a potent
- AI-Driven MRI Segmentation: A New Era in Radiology Efficiencyhttps://reachmd.com/news/ai-driven-mri-segmentation-a-new-era-in-radiology-efficiency/2471174/In a groundbreaking development, Swiss scientists have introduced an AI model that streamlines MRI image segmentation, promising to reduce radiologist workload and enhance diagnostic accuracy. The introduction of an AI model that efficiently seg
- Dupixent Moves Closer to FDA Approval for Bullous Pemphigoidhttps://reachmd.com/news/dupixent-moves-closer-to-fda-approval-for-bullous-pemphigoid/2471173/Dupixent® (dupilumab) significantly improved sustained disease remission in adults with bullous pemphigoid (BP) compared to placebo, according to an announcement from the manufacturers, Regeneron Pharmaceuticals and Sanofi. Acc